A multicenter phase II trial of irinotecan (CPT-11) plus raltitrexed (ZD) in patients with 5-fluorouracil-refractory, advanced colorectal cancer (ACC):: Preliminary results.

被引：0
|
作者：
Aparicio, J
de las Peñas, R
Vicent, JM
Garcerá, S
Maestu, I
Llorca, C
Bosch, C
Yuste, A
Frau, A
Farrés, J
机构：
[1] Hosp La Fe, E-46009 Valencia, Spain
[2] Hosp Prov, Castellon, Spain
[3] Gen Hosp, Valencia, Spain
[4] Hosp La Ribera, Alzira, Spain
[5] Hosp V Lirios, Alcoy, Spain
[6] Gen Hosp, Elda, Spain
[7] Hosp Dr Peset, Valencia, Spain
[8] Prasfarma, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
195P
引用
收藏
页码：45 / 45
页数：1
相关论文
共 50 条
  • [1] Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer
    Aparicio, J
    Vicent, JM
    Maestu, I
    Garcerá, S
    Busquier, I
    Bosch, C
    Llorca, C
    Díaz, R
    Fernández-Martos, C
    Galán, A
    ANNALS OF ONCOLOGY, 2003, 14 (07) : 1121 - 1125
  • [2] Phase II study of irinotecan (CPT-11) in patients with 5-Fluorouracil-refractory metastatic colorectal carcinoma - An Asian experience
    Ang, PCS
    Koo, WH
    Au, E
    Ang, PT
    Khoo, KS
    ANNALS OF ONCOLOGY, 1998, 9 : 45 - 45
  • [3] Irinotecan (CPT-11) in combination with raltitrexed (TX) in patients with previously untreated, advanced colorectal cancer (ACC) patients.: Preliminary results of a phase I/II trial.
    Losa, F
    Manzano, H
    Vicente, P
    Rifa, J
    Ocaña, J
    Balcells, M
    Mediavilla, D
    Heras, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 288S - 288S
  • [4] Irinotecan (CPT-11) plus raltitrexed as second line chemotherapy (CT) in metastatic colorectal cancer: A phase II study. Preliminary results.
    Caroti, C
    Aschele, C
    Mammoliti, S
    D'Amico, M
    Torrisi, R
    Gallo, L
    ANNALS OF ONCOLOGY, 2000, 11 : 65 - 65
  • [5] Folinic acid (FA) and 5-fluorouracil (FU) alone or with irinotecan (CPT-11) for advanced colorectal cancer (ACC): Preliminary results of a randomized phase II trial
    Maiello, E
    Giuliani, F
    Gebbia, V
    Cigolari, S
    Fortunato, S
    Paoletti, G
    Borsellino, N
    Lopez, M
    Gebbia, N
    Colucci, G
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S71 - S71
  • [6] Phase II trial of irinotecan (CPT-11) in patients with 5-FU resistant advanced colorectal cancer
    Vicent, JM
    Aparicio, J
    Lizon, J
    Molins, C
    Alonso, JD
    Gimenez-Arnau, JM
    Camps, C
    Segura, A
    Rizo, A
    Xarles, J
    ANNALS OF ONCOLOGY, 1998, 9 : 44 - 45
  • [7] Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractor advanced colorectal cancer
    Aparicio, J
    de las Peñas, R
    Vicent, JM
    Garcerá, S
    Llorca, C
    Maestu, I
    Yuste, AL
    Farrés, J
    ONCOLOGY, 2002, 63 (01) : 42 - 47
  • [8] Phase II study of irinotecan (CPT-11) in patients with advanced colorectal cancer resistant to 5-fluorouracil based chemotherapy.
    Salinas, P
    Lara, MA
    de Septién, CFM
    Feliu, J
    Espinosa, E
    de Castro, J
    García-Girón, C
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S76 - S76
  • [9] A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
    Rothenberg, ML
    Cox, JV
    DeVore, RF
    Hainworth, JD
    Pazdur, R
    Rivkin, SE
    Macdonald, JS
    Geyer, CE
    Sandbach, J
    Wolf, SL
    Mohrland, JS
    Elfring, GL
    Miller, LL
    Von Hoff, DD
    CANCER, 1999, 85 (04) : 786 - 795
  • [10] Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy
    Aravantinos, G
    Skarlos, DV
    Kosmidis, P
    Georgoulias, V
    Sgouros, I
    Bafaloukos, D
    Androulakis, N
    Florou, S
    Fountzilas, G
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1999, 32 (03) : 209 - 219
12345